WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases, announced financial results for the first quarter ended March 31, 2026, and highlighted recent corporate developments. For the first quarter, total net revenue was $0.7 million, compared with $24.5 million for the same period in 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the company’s 2023 agreement for the license of Yutiq product rights, a treatment for chronic non-infectious uveitis, the announcement said. EyePoint also reported net nonoperating income totaling $2.3 million and a net loss of $84.8 million, compared with a net loss of $45.2 million for the same period in 2025.